Skip to main content
. Author manuscript; available in PMC: 2018 Mar 1.
Published in final edited form as: Cancer Immunol Res. 2017 Aug 3;5(9):790–803. doi: 10.1158/2326-6066.CIR-17-0009

Figure 5. Reg suppressed melanoma tumor progression and promoted intratumoral CD45+ leukocyte and CD8+ T-cell accumulation.

Figure 5

(A–B) B16-F1 tumor-bearing mice were treated with Reg (8 mg/kg) and/or NU7026 (6 mg/kg) and tumor volume (A) and survival (B) were monitored (n = 5–6/group). Differences for tumor volumes were determined on days 15–33 by one-way ANOVA with Tukey post-test and log-rank test for survival comparing vehicle to either Reg or Reg+NU groups. On days 15 and 16, intratumoral CD45+ leukocytes (C) and CD8+ T cells (D–E) were measured. CD8+ T cells were normalized to either tumor cell number (D) or as a percentage of the CD45+ population (E). Differences in C–E were assessed using one-way ANOVA with Tukey post-test. ‘NU’ = NU7026. All results are representative of two independent experiments and show mean ± SEM. *, P < 0.05, **, P < 0.01, ***, P < 0.001.